---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-033348"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:18:14.914242+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q3 2025 revenue $86k, GAAP net loss ($19.4M), cash $95.2M

## Summary
- Revenue of $86k from limited market release of nPulse Vybrance system.
- GAAP net loss ($19.4M) vs ($12.7M) in Q3 2024; Non-GAAP net loss ($13.5M) vs ($9.4M).
- Cash $95.2M at Sep 30, 2025; operating cash burn $13.0M in Q3 2025.
- Enrolled 40% of subjects in PRECISE-BTN thyroid nodule study; FDA IDE approved for NANOCLAMP AF surgical trial.
- Treated 150 patients with nsPFA 360° catheter in European AF feasibility study; IDE submission filed.

## SEC filing metadata
- accession: 0001437749-25-033348
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925033348/0001437749-25-033348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925033348/plse20250826_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-033348
- JSON: https://secwatch.observer/filing/0001437749-25-033348.json
- Plain text: https://secwatch.observer/filing/0001437749-25-033348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.